Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Analysis of Revascularisation in Ischemic Stroke With EmboTrap (ARISE)

16 november 2018 uppdaterad av: Neuravi Limited

A.R.I.S.E. Analysis of Revascularisation in Ischemic Stroke With EmboTrap: Post Marketing Observational Study of CE Marked EmboTrap Mechanical Thrombectomy Device

A.R.I.S.E. is a post approval observational study using standard care. The purpose of this study is to collect information about the ability of the EmboTrap device to remove blood clots from the brain, and the associated performance characteristics and clinical outcomes. No formal hypothesis testing is needed as no comparisons are planned within the study. Instead, estimates of each population parameter of interest for all primary and secondary endpoints will be provided using appropriate confidence intervals.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Observationell

Inskrivning (Faktisk)

40

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Aarhus, Danmark
        • Aarhus University Hospital
      • Dublin, Irland
        • Beaumont Hospital
      • Barcelona, Spanien
        • Hospital Clínico de Barcelona
      • Solna, Sverige, 17176
        • Karolinska Institutet
      • Kiel, Tyskland
        • Universitätsklinikum Kiel

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Ischemic stroke patients

Beskrivning

Inclusion Criteria:

  • The patient or the patient's legally authorized representative has signed and dated an Informed Consent Form.
  • Aged between 18 years and 80 years (inclusive).
  • A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
  • NIHSS score ≥8 and ≤25.
  • Pre-ictal mRS score of 0 or 1.
  • Angiographic confirmation of an occlusion of an ICA (including T and L occlusions), M1 or M2, MCA, or BA with TICI flow of 0-1.
  • Confirmation by the interventionalist, after screening CT or MRI, that the treatment site can be accessed with the Neuravi device.
  • The interventionalist estimates that at least one deployment of the Neuravi device can be completed within 5 hours from the onset of symptoms, or if time of onset of symptoms is unknown or > 5 hours, patients can be included using imaging with the following criteria:

    1. MRI criterion: ASPECTS 8 to 10, or,volume of diffusion restriction ≤30 mL and mismatch between perfusion reduction and diffusion restriction present.
    2. CT criterion: ASPECTS 8 to 10 on baseline CT or CTA-source images, or, volume of significantly lowered CBV ≤30 mL and mismatch between perfusion reduction and low CBV present.

Exclusion Criteria:

  • Life expectancy of less than 6 months.
  • Females who are pregnant or lactating.
  • History of severe allergy to contrast medium.
  • Has suffered a stroke in the past three months.
  • The patient presents with an NIHSS score <8 or >25 or is physician assessed as being in a clinically relevant uninterrupted coma.
  • Use of warfarin anticoagulation with International Normalized Ratio (INR) > 3.0.
  • Platelet count < 50,000.
  • Glucose < 50 mg/dL.
  • Heparin use in previous 24 hours with PTT or ACT > 2X normal.
  • Any known hemorrhagic or coagulation deficiency.
  • Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
  • For basilar artery occlusion, extended early ischemic changes as confirmed by pc-ASPECTS ≤ 7 on baseline CT or CTA-source images, or extensive DWI lesions in the midbrain or pons regions on pre-treatment MRI.
  • Baseline CT or MRI showing mass effect or intracranial tumor (except small meningioma).
  • Excessive arterial tortuosity that precludes the study device from reaching the target vessel.
  • A proximal stenosis or complete occlusion that cannot, as judged by the responsible interventionalist, be treated safely or which prevents access to the occluded vessel with the Neuravi device.
  • Evidence of active infection.
  • Known cancer with metastases
  • Current use of cocaine or other vasoactive substance.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Kohort
  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
EmboTrap® Revascularization Device
The EmboTrap® Revascularization Device is the investigational device
Andra namn:
  • EmboTrap

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of Revascularisation Following the Use of the Neuravi Device.
Tidsram: Day 1

Revascularisation is defined as achieving a modified Thrombolysis in Cerebrovascular Infarction (mTICI) score of 2b or greater.

mTICI is a 6-point grading system for determining the response of thrombolytic therapy for ischaemic stroke:

mTICI 0 = No perfusion

mTICI 1 = Penetration but not perfusion

mTICI 2a = Some perfusion with distal branch filling of <50% of territory visualized

mTICI 2b = Substantial perfusion with distal branch filling of ≥50% of territory visualized

mTICI 2c = Near-complete perfusion

mTICI 3 = Complete perfusion

Day 1

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to Revascularization
Tidsram: Day 1
Defined as time from groin puncture to visualization of final angiographic result.
Day 1
Mortality Post Procedure
Tidsram: 7 and 90(±14) days post procedure
All procedure related mortality (i.e. directly traceable to a procedure related SAE).
7 and 90(±14) days post procedure
Serious Adverse Device Related Effects (SADE)
Tidsram: 24(-8/+12) hours Post Procedure
SADE is defined as vessel perforation or vessel dissection, which is attributable to the Neuravi device, or where the Neuravi device cannot be ruled out as the cause.
24(-8/+12) hours Post Procedure
Symptomatic ICH
Tidsram: 24(-8/+12) hours Post Procedure

Symptomatic ICH rate within 24 hours (range: 16 to 36 hours) post-procedure. Symptomatic intracranial haemorrhage (parenchymatous haemorrhage type 2), at post-treatment scan combined with neurological deterioration (C2) leading to an increase of 4 points or more on the NIH Stroke Scale.

The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. NIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.

24(-8/+12) hours Post Procedure
Clinical Outcome at 90 Days
Tidsram: 90(±14) days Post Procedure

A good clinical outcome will be judged to be a mRS score of ≤2 at 90(±14) days.

mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. mRS scores range from 0 to 6:

mRS 0 = No symptoms.

mRS 1 = No significant disability.

mRS 2 = Slight disability.

mRS 3 = Moderate disability.

mRS 4 = Moderately severe disability.

mRS 5 = Severe disability.

mRS 6 = Dead.

90(±14) days Post Procedure
Rate of New Territory Embolization
Tidsram: 24(-8/+12) hours Post Procedure
Embolization, or thrombus dislocation, into a previously uninvolved vascular territory as evaluated from angiographic images by the Angiography Core Lab and the Data Safety Monitoring Board.
24(-8/+12) hours Post Procedure
Evidence of Infarction
Tidsram: 24(-8/+12) hours Post Procedure
Infarction, of a previously uninvolved vascular territory, as evaluated from 24hr Computed Tomography imaging by the Angiography Core lab.
24(-8/+12) hours Post Procedure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Dr. Tommy Andersson, Karolinska Institutet
  • Huvudutredare: Prof. Dr. Heinrich Mattle, University Hospital Inselspital, Berne

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 november 2014

Primärt slutförande (Faktisk)

1 maj 2016

Avslutad studie (Faktisk)

1 januari 2018

Studieregistreringsdatum

Först inskickad

10 juli 2014

Först inskickad som uppfyllde QC-kriterierna

11 juli 2014

Första postat (Uppskatta)

15 juli 2014

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 mars 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2018

Senast verifierad

1 november 2018

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera